MS

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.
Post Reply
User avatar
Petr75
Family Elder
Posts: 921
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic

MS

Post by Petr75 » Sat Aug 15, 2020 5:21 am

2020 Jul 4
Department of Neurology, Helsinki University Hospital
The retirement rate due to multiple sclerosis has decreased since 1995- A retrospective study in a Finnish central hospital
https://pubmed.ncbi.nlm.nih.gov/32688302/

Abstract

Background: Multiple sclerosis (MS) is the most common cause of non-traumatic neurological disability affecting young adults during their best working years. Previous studies have shown that approximately two-thirds of patients with MS (PwMS) are unable to retain employment in the long term, and many retire soon after the diagnosis. However, it is not known, how the rate of retirement has changed over the decades, especially after the introduction of disease modifying therapies (DMTs). The year 1995 was selected as a division point because DMTs have been increasingly available ever since.

Objective: To evaluate the change in retirement rate due to MS and to present risk factors for early retirement.

Methods: A retrospective survey of all PwMS treated at the Department of Neurology, Kanta-Häme Central Hospital, Finland between 1978 and 2015, was conducted. The population was divided into two groups: those diagnosed before year 1995 and those diagnosed thereafter. A Kaplan-Meier analysis was performed to evaluate the time from diagnosis to beginning of a pension in both groups. Crude incidence rates, incidence rate differences as well as age and multivariable adjusted Cox proportional hazard regression analysis were calculated for all pension predictors collected.

Results: A total of 484 PwMS were identified, 140 of whom were diagnosed before the year 1995 and 344 after. Actual retirement rates were 88 (63%) before the year the year 1995 and 111 (32%) after, respectively. The hazard for disability pension diminished in PwMS diagnosed after the year 1995 compared to those diagnosed before, HR 0.41 (95% confidence interval 0.31-0.55). The median time from diagnosis to retirement was 8.3 years in the group diagnosed before year 1995 and 11.1 years in the group diagnosed later. Male sex and age were statistically significant risk factors in relapsing-remitting MS, HR for male sex 1.8 (95% confidence interval 1.18-2.75) and for age 1.1 (95% confidence interval 1.07-1.12). Only age was a risk factor in progressive MS with HR 1.09 (95% confidence interval 1.07-1.11). In subgroup of relapsing-remitting MS, not using disease modifying therapies was a statistically significant risk factor, HR 1.89 (95% confidence interval 1.19-3.01).

Conclusion: The rate of retirement due to MS in Finland has decreased significantly since 1995 and the median time from diagnosis to retirement has become longer. Not using disease modifying therapies for relapsing remitting MS was identified as one risk factor for losing ability to work prematurely.

User avatar
Petr75
Family Elder
Posts: 921
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic

Re: MS

Post by Petr75 » Sat Aug 15, 2020 8:56 pm


User avatar
Petr75
Family Elder
Posts: 921
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic

Re: MS

Post by Petr75 » Sat Aug 15, 2020 9:03 pm

2019 May
Department of Neurology, Harvard Medical School, Boston, MA, USA; Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston
Time between expanded disability status scale (EDSS) scores
https://pubmed.ncbi.nlm.nih.gov/30763908/

Abstract

Background: Although the expanded disability status scale (EDSS) is the most commonly used measure of disability for multiple sclerosis, measurement of disability accumulation is complex due to the unequal steps of the scale.

Objective: To estimate the time between EDSS scores in a large MS cohort from a single center and determine the impact of functional system scores on EDSS transitions.

Methods: 31,394 clinical visits with EDSS scores from 2054 subjects in the CLIMB longitudinal cohort study were included in our analysis. The time to each EDSS score and the time between each EDSS score were calculated using the nonparametric maximum likelihood estimate for interval censored data. For each initial EDSS value, the association between functional status scores and subsequent EDSS value was assessed using a mixed effects linear regression model, and the association with time to EDSS increase was assessed using a Cox proportional hazards model.

Results: The median time until EDSS 2, 3, 4, 5 and 6 in all subjects were 4.8, 15.1, 28.2, 31.2, and 32.4 years, respectively. The time intervals showed that the disability accumulation intervals from EDSS 4 to 6 were much shorter than the accumulation intervals from EDSS 0 to 3 or from EDSS 6 to 8. For EDSS of 1 or 1.5, pyramidal, cerebellar, sensory, bowel-bladder and mental system scores were associated with higher subsequent EDSS values. For higher EDSS values, only pyramidal and bowel-bladder scores maintained the association.

Conclusions: Time between specific EDSS levels varies considerably. Certain functional system scores have greater predictive power for future EDSS-related disability despite same present EDSS level. These findings will assist in adaptation of the EDSS as an outcome measure to assess MS-related disability in clinical trials.

User avatar
NHE
Volunteer Moderator
Posts: 5515
Joined: Sat Nov 20, 2004 3:00 pm
Contact:

Re: MS

Post by NHE » Sun Aug 16, 2020 3:57 am

Petr75 wrote:
Sat Aug 15, 2020 9:03 pm
2019 May
Department of Neurology, Harvard Medical School, Boston, MA, USA; Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston
Time between expanded disability status scale (EDSS) scores
https://pubmed.ncbi.nlm.nih.gov/30763908/

Image

User avatar
NHE
Volunteer Moderator
Posts: 5515
Joined: Sat Nov 20, 2004 3:00 pm
Contact:

Re: MS

Post by NHE » Mon Aug 17, 2020 7:50 am

Petr75 wrote:
Sat Aug 15, 2020 8:56 pm

http://www.msdiscovery.org/news/news_sy ... -meets-eye
3 Apr 2012
What's remarkable is that this patient had a complete absence of clinical symptoms despite their apparent prolific MRI lesion activity.

User avatar
Petr75
Family Elder
Posts: 921
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic

Re: MS

Post by Petr75 » Wed Sep 02, 2020 9:21 am

2020 Aug 6
From the Department of Neurology ,IRCCS (N.B.), Fondazione Don Carlo Gnocchi ONLUS, Milan, Italy
Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis
https://pubmed.ncbi.nlm.nih.gov/32763899/


Abstract

Background and purpose: It is unknown whether deceleration of brain atrophy is associated with disability improvement in patients with MS. Our aim was to investigate whether patients with MS with disability improvement develop less brain atrophy compared with those who progress in disability or remain stable.
Materials and methods: We followed 980 patients with MS for a mean of 4.8 ± 2.4 years. Subjects were divided into 3 groups: progress in disability (n = 241, 24.6%), disability improvement (n = 101, 10.3%), and stable (n = 638, 65.1%) at follow-up. Disability improvement and progress in disability were defined on the basis of the Expanded Disability Status Scale score change using standardized guidelines. Stable was defined as nonoccurrence of progress in disability or disability improvement. Normalized whole-brain volume was calculated using SIENAX on 3D T1WI, whereas the lateral ventricle was measured using NeuroSTREAM on 2D-T2-FLAIR images. The percentage brain volume change and percentage lateral ventricle volume change were calculated using SIENA and NeuroSTREAM, respectively. Differences among groups were investigated using ANCOVA, adjusted for age at first MR imaging, race, T2 lesion volume, and corresponding baseline structural volume and the Expanded Disability Status Scale.
Results: At first MR imaging, there were no differences among progress in disability, disability improvement, and the stable groups in whole-brain volume (P = .71) or lateral ventricle volume (P = .74). During follow-up, patients with disability improvement had the lowest annualized percentage lateral ventricle volume change (1.6% ± 2.7%) followed by patients who were stable (2.1% ± 3.7%) and had progress in disability (4.1% ± 5.5%), respectively (P < .001). The annualized percentage brain volume change values were -0.7% ± 0.7% for disability improvement, -0.8% ± 0.7% for stable, and -1.1% ± 1.1% for progress in disability (P = .001).
Conclusions: Patients with MS who improve in their clinical disability develop less brain atrophy across time compared with those who progress.

User avatar
Petr75
Family Elder
Posts: 921
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic

Re: MS

Post by Petr75 » Sat Sep 05, 2020 8:48 pm

2020 Aug 10
Neuroimmune Interactions Laboratory, Institute of Biomedical Sciences, Department of Immunology, University of Sao Paulo, São Paulo, Brazil
Neuroinflammation at single cell level: What is new?
https://pubmed.ncbi.nlm.nih.gov/32779279/

Abstract

Multiple sclerosis is a chronic and demyelinating disease of the central nervous system (CNS), most prevalent in women, and with an important social and economic cost worldwide. It is triggered by self-reacting lymphocytes that infiltrate the CNS and initiate neuroinflammation. Further, axonal loss and neuronal death takes place, leading to neurodegeneration and brain atrophy. The murine model for studying MS, experimental autoimmune encephalomyelitis (EAE), consists in immunizing mice with myelin-derived epitopes. APCs activate encephalitogenic T CD4 and CD8 lymphocytes that migrate mainly to the spinal cord resulting in neuroinflammation. Most of the knowledge on the pathophysiology and treatment of MS was obtained from EAE experiments, as Th17 cells, anti-alpha4 blocking Abs and the role of microbiota. Conversely, recent technology breakthroughs, such as CyTOF and single-cell RNA-seq, promise to revolutionize our understanding on the mechanisms involved both in MS and EAE. In fact, the importance of specific cellular populations and key molecules in MS/EAE is a constant matter of debate. It is well accepted that both Th1 and Th17 T CD4 lymphocytes play a relevant role in disease initiation after re-activation in situ. What is still under constant investigation, however, is the plasticity of the lymphocyte population, and the individual contribution of both resident and inflammatory cells for the progression or recovery of the disease. Thus, in this review, new findings obtained after single-cell analysis of blood and central nervous system infiltrating cells from MS/EAE and how they have contributed to a better knowledge on the cellular and molecular mechanisms of neuroinflammation are discussed.

User avatar
Petr75
Family Elder
Posts: 921
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic

Re: MS

Post by Petr75 » Tue Sep 15, 2020 5:55 am

2020 Aug 18
Department of Radiology and Imaging Sciences, School of Medicine, Emory University, Atlanta
Patient-reported financial toxicity in multiple sclerosis: Predictors and association with care non-adherence
https://pubmed.ncbi.nlm.nih.gov/32808562/

Abstract

Background: Multiple sclerosis (MS) results in considerable financial burdens due to expensive treatment and high rates of disability, which could both impact care non-adherence.

Objective: To measure financial toxicity in MS patients, identify its predictors and association with care non-adherence.

Methods: Adult MS patients visiting neurology clinic (June 2018 to February 2019) were consented to complete a survey. Financial toxicity was measured using Comprehensive Score for Financial Toxicity (COST) (range: 0-44, the lower the score, the worse the financial toxicity). Independent predictors of financial toxicity were identified using linear regression. Associations of COST score with patient outcomes were assessed.

Results: The mean COST score in 243 recruited patients was 17.4 ± 10.2. In response to financial burdens, 66.7% and 34.7% reported life-style altering behaviors or care non-adherence, respectively. Higher financial self-efficacy was associated with less financial toxicity (coefficient, 1.33 (95% confidence interval (CI), 1.02-1.64); p < 0.001). At least one relapse in the last 3 months was associated with greater financial toxicity (coefficient, -3.34 (95% CI, -6.66 to -0.01); p = 0.049). Greater financial toxicity correlated with life-style-altering coping strategy use (p < 0.001), care non-adherence (p = 0.001), and worse health-related quality of life (HRQOL) (p = 0.03).

Conclusion: MS patients with lower financial self-efficacy and prior relapse history are at higher risk for financial toxicity, with associated care non-adherence and lower HRQOL.

Post Reply

Return to “General Discussion”